The EFHD1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated via targeted disruption of the EFHD1 gene. This loss-of-function model enables robust investigation of EFHD1’s roles in mitochondrial dynamics, cell migration, and apoptosis without the artifacts of clonal selection, utilizing the highly transfectable HEK293T host.
HEK293T cells are a transformed human embryonic kidney line stably expressing the SV40 large T antigen, widely utilized for transient protein expression, viral packaging, and gene editing applications. Their exceptionally high transfection efficiency and well-characterized biology provide an optimal background for functional genomic studies. The adherent epithelial morphology facilitates live-cell imaging and functional assays, making them a versatile platform for dissecting complex cellular pathways.
EFHD1 is a calcium-binding protein that senses intracellular Ca2? and regulates mitochondrial fission, actin dynamics, and apoptosis. It directly interacts with DRP1, VDAC, IP3R, and actin, positioning it at ER-mitochondria contact sites. Upstream activation occurs via calcium signaling, reactive oxygen species, and growth factor stimulation. Downstream, EFHD1 modulates DRP1-mediated mitochondrial fission, actin polymerization, and pro-apoptotic Bcl-2 family proteins such as Bax and Bak. It operates within the calcium/calmodulin/calcineurin/NFAT signaling axis. Gene disruption leads to mitochondrial fragmentation, cytoskeletal defects, and altered apoptosis.
In HEK293T cells, EFHD1 knockout provides a tractable model for studying calcium-dependent mitochondrial dysfunction and cell migration. The polyclonal pool avoids single-clone adaptation biases. High transfection efficiency allows complementation with wild-type or mutant EFHD1 constructs to dissect structure-function relationships. EFHD1’s roles in cancers such as melanoma and breast cancer and in neurodegenerative diseases like Alzheimer’s can be explored through metabolic flux analyses and migration assays, leveraging HEK293T’s robust metabolic activity.
These cells are suited for MitoTracker staining to assess mitochondrial morphology, scratch-wound and Transwell migration assays, Annexin V and caspase assays for apoptosis, and calcium imaging for monitoring intracellular Ca2? dynamics. Co-immunoprecipitation and Western blotting confirm protein interactions with DRP1, VDAC, and actin, while RT-qPCR profiles NFAT-driven transcriptional changes. Metabolic analysis via Seahorse to measure oxygen consumption and extracellular acidification complements mechanistic studies. This polyclonal knockout model supports functional genomics, drug target validation, and pathway dissection in cancer and mitochondrial disease research. For further details, please contact Ascent Research.
